Equities research analysts predict that Regeneron Pharmaceuticals Inc (NASDAQ:REGN) will report $1.70 billion in sales for the current fiscal quarter, Zacks Investment Research reports. Seven analysts have made estimates for Regeneron Pharmaceuticals’ earnings, with the highest sales estimate coming in at $1.77 billion and the lowest estimate coming in at $1.61 billion. Regeneron Pharmaceuticals posted sales of $1.58 billion in the same quarter last year, which would indicate a positive year over year growth rate of 7.6%. The company is scheduled to announce its next earnings results on Thursday, February 14th.
On average, analysts expect that Regeneron Pharmaceuticals will report full-year sales of $6.48 billion for the current fiscal year, with estimates ranging from $6.32 billion to $6.56 billion. For the next fiscal year, analysts anticipate that the business will post sales of $7.18 billion, with estimates ranging from $6.81 billion to $7.83 billion. Zacks’ sales averages are an average based on a survey of sell-side research firms that follow Regeneron Pharmaceuticals.
Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its earnings results on Tuesday, November 6th. The biopharmaceutical company reported $5.87 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $4.94 by $0.93. Regeneron Pharmaceuticals had a return on equity of 30.24% and a net margin of 28.24%. The firm had revenue of $1.66 billion during the quarter, compared to analyst estimates of $1.64 billion. During the same period in the previous year, the company earned $3.99 EPS. The company’s revenue for the quarter was up 10.8% on a year-over-year basis.
Shares of REGN stock traded down $8.86 during trading hours on Monday, reaching $372.83. 835,844 shares of the company’s stock were exchanged, compared to its average volume of 626,753. Regeneron Pharmaceuticals has a fifty-two week low of $281.89 and a fifty-two week high of $416.49. The firm has a market cap of $41.30 billion, a PE ratio of 27.80, a price-to-earnings-growth ratio of 1.63 and a beta of 1.36. The company has a quick ratio of 3.30, a current ratio of 4.04 and a debt-to-equity ratio of 0.09.
In other Regeneron Pharmaceuticals news, Director Joseph L. Goldstein sold 2,000 shares of the company’s stock in a transaction on Monday, September 24th. The stock was sold at an average price of $388.65, for a total value of $777,300.00. Following the sale, the director now directly owns 13,000 shares in the company, valued at $5,052,450. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 12.42% of the company’s stock.
A number of large investors have recently made changes to their positions in the business. Rehmann Capital Advisory Group grew its position in Regeneron Pharmaceuticals by 1,700.0% in the third quarter. Rehmann Capital Advisory Group now owns 72 shares of the biopharmaceutical company’s stock valued at $29,000 after acquiring an additional 68 shares during the period. Vanguard Group Inc. grew its holdings in shares of Regeneron Pharmaceuticals by 1.3% during the third quarter. Vanguard Group Inc. now owns 5,754,927 shares of the biopharmaceutical company’s stock worth $2,325,220,000 after purchasing an additional 75,868 shares during the last quarter. Morgan Stanley grew its holdings in shares of Regeneron Pharmaceuticals by 70.6% during the third quarter. Morgan Stanley now owns 464,603 shares of the biopharmaceutical company’s stock worth $187,719,000 after purchasing an additional 192,236 shares during the last quarter. Legal & General Group Plc grew its holdings in shares of Regeneron Pharmaceuticals by 2.5% during the third quarter. Legal & General Group Plc now owns 360,002 shares of the biopharmaceutical company’s stock worth $145,455,000 after purchasing an additional 8,792 shares during the last quarter. Finally, Kepos Capital LP bought a new stake in shares of Regeneron Pharmaceuticals during the third quarter worth $1,928,000. Hedge funds and other institutional investors own 67.24% of the company’s stock.
About Regeneron Pharmaceuticals
Regeneron Pharmaceuticals, Inc, a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating serious medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.
Featured Article: What is the quiet period?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.